-
Je něco špatně v tomto záznamu ?
Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides
P. Perlíková, M. Hocek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
PubMed
28834581
DOI
10.1002/med.21465
Knihovny.cz E-zdroje
- MeSH
- antivirové látky chemická syntéza chemie farmakologie MeSH
- buňky A549 MeSH
- buňky Hep G2 MeSH
- HeLa buňky MeSH
- lidé MeSH
- nukleosidy chemická syntéza chemie farmakologie MeSH
- protinádorové látky chemická syntéza chemie farmakologie MeSH
- puriny chemie MeSH
- racionální návrh léčiv MeSH
- screeningové testy protinádorových léčiv MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
7-Deazapurine (pyrrolo[2,3-d]pyrimidine) nucleosides are important analogues of biogenic purine nucleosides with diverse biological activities. Replacement of the N7 atom with a carbon atom makes the five-membered ring more electron rich and brings a possibility of attaching additional substituents at the C7 position. This often leads to derivatives with increased base-pairing in DNA or RNA or better binding to enzymes. Several types of 7-deazapurine nucleosides with potent cytostatic or cytotoxic effects have been identified. The most promising are 7-hetaryl-7-deazaadenosines, which are activated in cancer cells by phosphorylation and get incorporated both to RNA (causing inhibition of proteosynthesis) and to DNA (causing DNA damage). Mechanism of action of other types of cytostatic nucleosides, 6-hetaryl-7-deazapurine and thieno-fused deazapurine ribonucleosides, is not yet known. Many 7-deazaadenosine derivatives are potent inhibitors of adenosine kinases. Many types of sugar-modified derivatives of 7-deazapurine nucleosides are also strong antivirals. Most important are 2'-C-methylribo- or 2'-C-methyl-2'-fluororibonucleosides with anti-HCV activities (several compounds underwent clinical trials). Some underexplored areas of potential interest are also outlined.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024716
- 003
- CZ-PrNML
- 005
- 20180716122725.0
- 007
- ta
- 008
- 180709s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/med.21465 $2 doi
- 035 __
- $a (PubMed)28834581
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Perlíková, Pavla $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, CZ-16610, Prague 6, Czech Republic.
- 245 10
- $a Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides / $c P. Perlíková, M. Hocek,
- 520 9_
- $a 7-Deazapurine (pyrrolo[2,3-d]pyrimidine) nucleosides are important analogues of biogenic purine nucleosides with diverse biological activities. Replacement of the N7 atom with a carbon atom makes the five-membered ring more electron rich and brings a possibility of attaching additional substituents at the C7 position. This often leads to derivatives with increased base-pairing in DNA or RNA or better binding to enzymes. Several types of 7-deazapurine nucleosides with potent cytostatic or cytotoxic effects have been identified. The most promising are 7-hetaryl-7-deazaadenosines, which are activated in cancer cells by phosphorylation and get incorporated both to RNA (causing inhibition of proteosynthesis) and to DNA (causing DNA damage). Mechanism of action of other types of cytostatic nucleosides, 6-hetaryl-7-deazapurine and thieno-fused deazapurine ribonucleosides, is not yet known. Many 7-deazaadenosine derivatives are potent inhibitors of adenosine kinases. Many types of sugar-modified derivatives of 7-deazapurine nucleosides are also strong antivirals. Most important are 2'-C-methylribo- or 2'-C-methyl-2'-fluororibonucleosides with anti-HCV activities (several compounds underwent clinical trials). Some underexplored areas of potential interest are also outlined.
- 650 _2
- $a buňky A549 $7 D000072283
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
- 650 _2
- $a antivirové látky $x chemická syntéza $x chemie $x farmakologie $7 D000998
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nukleosidy $x chemická syntéza $x chemie $x farmakologie $7 D009705
- 650 _2
- $a puriny $x chemie $7 D011687
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hocek, Michal $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, CZ-16610, Prague 6, Czech Republic. Department of Organic Chemistry, Faculty of Science, Charles University in Prague, CZ-12843, Prague 2, Czech Republic.
- 773 0_
- $w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 37, č. 6 (2017), s. 1429-1460
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28834581 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180716123023 $b ABA008
- 999 __
- $a ok $b bmc $g 1316847 $s 1021637
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 37 $c 6 $d 1429-1460 $e 20170823 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
- LZP __
- $a Pubmed-20180709